Menopause and hormone replacement therapy. The 2017 recommendations of the Italian Menopause Society.

Menopause and hormone replacement therapy. The 2017 recommendations of the Italian Menopause Society. Minerva Ginecol. 2017 Oct 03;: Authors: Gambacciani M, Biglia N, Cagnacci A, DI Carlo C, Caruso S, Cicinelli E, DE Leo V, Farris M, Gambera A, Guaschino S, Lanzone A, Paoletti AM, Russo N, Vicariotto F, Villa P, Volpe A Abstract In the last decade the risk benefits ratio of HRT has been reevaluated mainly in tens of cardiovascular risk. Present Consensus Statement is largely inspired by the Global Consensus on Menopausel Hormone Therapy in 2013 and 2016 by leading global menopause societies (The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society). The aim of these Recommendations is to provide a simple and updated reference on postmenopausal HRT. The term HRT typically includes estrogen replacement therapy (ERT) and estrogen- progestogen therapy (EPT). EPT can be sequential (Seq) when progestogen is added to ERT for 10-14 days a month, or continuous combined (CC) when progestogen is administered continuously every day along with a fixed amount of estrogen, In the everyday language, HRT includes also Tibolone and the Tissue Selective Estrogen Complex (TSEC). PMID: 28975776 [PubMed - as supplied by publisher]
Source: Minerva Ginecologica - Category: OBGYN Tags: Minerva Ginecol Source Type: research

Related Links:

Source: BMJ Comments - Category: General Medicine Source Type: forums
Publication date: Available online 14 January 2019Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Tianshuang Xia, Xin Dong, Liuyue Lin, Yiping Jiang, Xueqin Ma, Hailiang Xin, Qiaoyan Zhang, Luping QinAbstractMorinda officinalis (MO) has long been used as a traditional herbal medicine for the treatment of bone fractures and joint diseases in China. Monotropein (Mon) and rubiadin-1-methyl ether (Rub) are major bioactive components in MO. Ample evidence shows that MO and its chemical constituents can prevent osteoporosis induced by estrogen-deficiency and ageing. However, there is no study reporting glucoc...
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research
Legal battle over Trump's exemptions to no-cost birth control rule may be bound for Supreme Court
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) updates the 2012 Hormone Therapy Position Statement of The North American Menopause Society and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women's health and menopause was recruited by NAMS to review the 2012 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence. The Panel's recommendations were reviewed and approved by...
Source: Menopause - Category: OBGYN Tags: Commemorative Papers Source Type: research
Calcium levels of 700-1200 mg/day are recommended in postmenopausal women, but excessive doses could be harmful, highlights a new clinical guide from the European Menopause and Andropause Society.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
(Elsevier) Osteoporosis is common and affects 1 in 3 women. Calcium is vital for strong healthy bones and worldwide scientific societies have issued guidance about the daily requirements from childhood to old age. The European Menopause and Andropause Society (EMAS) has issued a new clinical guide with the aim of raising awareness of the importance of calcium in lowering the risk of osteoporosis.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Abstract: The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) updates the 2012 Hormone Therapy Position Statement of The North American Menopause Society and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women's health and menopause was recruited by NAMS to review the 2012 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence. The Panel's recommendations were reviewed and a...
Source: Menopause - Category: OBGYN Tags: Position Statement Source Type: research
Authors: Golds G, Houdek D, Arnason T Abstract It is well recognized that bone loss accelerates in hypogonadal states, with female menopause being the classic example of sex hormones affecting the regulation of bone metabolism. Underrepresented is our knowledge of the clinical and metabolic consequences of overt male hypogonadism, as well as the more subtle age-related decline in testosterone on bone quality. While menopause and estrogen deficiency are well-known risk factors for osteoporosis in women, the effects of age-related testosterone decline in men on bone health are less well known. Much of our knowledge c...
Source: International Journal of Endocrinology - Category: Endocrinology Tags: Int J Endocrinol Source Type: research
The following Consensus Statement is endorsed by The International Menopause Society, The North American Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The Asia Pacific Menopause Federation, The International Osteoporosis Foundation and The Federation of Latin American Menopause Societies.
Source: Maturitas - Category: Primary Care Authors: Source Type: research
CONCLUSIONS: There is evidence to indicate an increase in bone mineral density at the femoral neck, lumbar spine and forearm after administration of bisphosphonates and at the lumbar spine and hip after zinc sulphate supplementation. The authors recommend that further long-term randomised control trials on different bisphosphonates and zinc supplementation therapies in people with beta-thalassaemia and osteoporosis are undertaken. PMID: 26964506 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: Journals (General) Authors: Tags: Cochrane Database Syst Rev Source Type: research
More News: Cardiology | Cardiovascular | Heart | Hormonal Therapy | Hormone Replacement Therapy | Hormones | Italy Health | Low Testosterone | Men | Menopause | OBGYN | Orthopaedics | Osteoporosis | USA Health